Advaxis, Inc. – OTC:ADXS
Advaxis stock price today
$0.053
+0.02
+96.3%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Advaxis stock price monthly change
-87.14%
month
Advaxis stock price quarterly change
-87.14%
quarter
Advaxis stock price yearly change
-95.85%
year
Advaxis key metrics
Market Cap | 3.72M |
Enterprise value | N/A |
P/E | -0.15 |
EV/Sales | -45.66 |
EV/EBITDA | 1.63 |
Price/Sales | 4.72 |
Price/Book | 0.10 |
PEG ratio | N/A |
EPS | -9.12 |
Revenue | N/A |
EBITDA | -35.92M |
Income | -48.07M |
Revenue Q/Q | -100% |
Revenue Y/Y | -97.97% |
Profit margin | -2871.8% |
Oper. margin | -3862% |
Gross margin | 0% |
EBIT margin | -3862% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAdvaxis stock price history
Advaxis stock forecast
Advaxis financial statements
| Mar 2023 | 4K | -7.36M | -184025% |
|---|---|---|---|
| Jun 2023 | 9K | -8.69M | -96655.56% |
| Sep 2023 | 0 | -7.33M | |
| Dec 2023 | 0 | -24.67M |
| Mar 2023 | 20995000 | 11.32M | 53.92% |
|---|---|---|---|
| Jun 2023 | 12151000 | 11.14M | 91.7% |
| Sep 2023 | 6981000 | 13.22M | 189.4% |
| Dec 2023 | 16579000 | 40.99M | 247.28% |
| Mar 2023 | -6.74M | 0 | 21.20M |
|---|---|---|---|
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | -6.98M | -5.21M | 2M |
| Dec 2023 | -7.20M | 5.94M | 4M |
Advaxis alternative data
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 14 |
| Jan 2024 | 14 |
| Feb 2024 | 14 |
| Mar 2024 | 14 |
| Apr 2024 | 14 |
| May 2024 | 14 |
| Jun 2024 | 14 |
| Jul 2024 | 14 |
Advaxis other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 0 | 0 |
| Oct 2023 | 1317716 | 0 |
| Patent |
|---|
Application Filling date: 18 Oct 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 29 Aug 2018 Issue date: 23 Nov 2021 |
Application Listeria-Based Compositions Comprising a Peptide Minigene Expression System and Methods of Use Thereof Filling date: 18 Dec 2020 Issue date: 12 Aug 2021 |
Application Filling date: 25 Apr 2019 Issue date: 5 Aug 2021 |
Application Filling date: 8 Nov 2018 Issue date: 17 Jun 2021 |
Grant Utility: Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof Filling date: 3 Mar 2016 Issue date: 26 Jan 2021 |
Application Filling date: 8 Mar 2019 Issue date: 7 Jan 2021 |
Application Filling date: 29 Aug 2018 Issue date: 20 Aug 2020 |
Application Filling date: 1 Nov 2019 Issue date: 5 Mar 2020 |
Application Filling date: 7 Nov 2017 Issue date: 27 Feb 2020 |
| Quarter | Transcript |
|---|---|
| Q2 2020 11 Jun 2020 | Q2 2020 Earnings Call Transcript |
| Q2 2019 11 Jun 2019 | Q2 2019 Earnings Call Transcript |
| Q4 2018 15 Jan 2019 | Q4 2018 Earnings Call Transcript |
| Q3 2018 2 Nov 2018 | Q3 2018 Earnings Call Transcript |
-
What's the price of Advaxis stock today?
One share of Advaxis stock can currently be purchased for approximately $0.05.
-
When is Advaxis's next earnings date?
Unfortunately, Advaxis's (ADXS) next earnings date is currently unknown.
-
Does Advaxis pay dividends?
No, Advaxis does not pay dividends.
-
How much money does Advaxis make?
Advaxis has a market capitalization of 3.72M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 94.8% to 13K US dollars.
-
What is Advaxis's stock symbol?
Advaxis, Inc. is traded on the OTC under the ticker symbol "ADXS".
-
What is Advaxis's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Advaxis?
Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Advaxis's key executives?
Advaxis's management team includes the following people:
- Mr. Kenneth A. Berlin J.D. Pres, Interim Chief Financial Officer, Chief Executive Officer & Director(age: 61, pay: $1,160,000)
- Dr. Andres A. Gutierrez M.D., Ph.D. Executive Vice President & Chief Medical Officer(age: 64, pay: $624,260)
-
How many employees does Advaxis have?
As Jul 2024, Advaxis employs 14 workers.
-
When Advaxis went public?
Advaxis, Inc. is publicly traded company for more then 20 years since IPO on 28 Jul 2005.
-
What is Advaxis's official website?
The official website for Advaxis is ayalapharma.com.
-
Where are Advaxis's headquarters?
Advaxis is headquartered at 305 College Rd E, Princeton, NEW JERSEY.
-
How can i contact Advaxis?
Advaxis's mailing address is 305 College Rd E, Princeton, NEW JERSEY and company can be reached via phone at +1 732 545 1590.
Advaxis company profile:
Advaxis, Inc.
ayalapharma.comExchange:
OTC
Full time employees:
35
Industry:
Biotechnology
Sector:
Healthcare
Advaxis, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III RINGSIDE clinical trial for the treatment of desmoid tumors. Advaxis, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Monmouth Junction, New Jersey.
305 College Rd E
Princeton, NEW JERSEY 08852
Princeton, NEW JERSEY 08852
CIK: 0001100397
ISIN: US0076243072
CUSIP: 007624307
